🏥TACE plus+ treatments in HCC
2 recent trials @TheLancet 

➡️EMERALD-1
✅TACE-durva-beva vs. TACE
PFS: 15 vs 8.2 mo, HR:0·77 (95% CI 0·61–0·98), p=0·032
❌TACE-durva vs. TACE: 
PFS: 10 vs 8.2 mo

➡️LEAP-012
✅TACE-pembro-lenva vs. TACE
PFS: 14.6 vs. 10 mo, HR: 0·66 (95% CI 0·51–0·8); one-sided p=0·0002

⁉️TACE plus beva alone?
⏱️TACE-atezo-beva, pilot study, NCT05776875

@TheLancetOncol @OncoAlert @brunolarvol  #cancer #oncology #MedX